REMI — Remedent Share Price
Last trade - 00:00- $0.20m
- $0.20m
- $1.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.04 | ||
| Price to Tang. Book | 0.04 | ||
| Price to Free Cashflow | 0.81 | ||
| Price to Sales | 0.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.29% | ||
| Return on Equity | -5.49% | ||
| Operating Margin | -9.45% | ||
Financial Summary
| Year End 31st Mar | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.77 | 2.36 | 2.7 | 1.6 | 1.06 | n/a | n/a | -21.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +52.85 | -79.23 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Remedent, Inc. specializes in the research, development and manufacturing of oral care and cosmetic dentistry products. The Company designs, develops, manufactures and distributes its cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, Middle East and the United States. The Company's operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Remedent N.V., and Biotech Dental Benelux N.V. The Company offers over-the-counter (OTC) tooth whitening products. It has three primary products: River 8, a prefabricated veneer; its custom-made GlamSmile Veneers and the SmileMe mirror. The Company has developed a range of prefabricated, ready-to-use veneers that the Company has branded as River8. The Company's product in the professional oral care and cosmetic dentistry is the GlamSmile veneer. The SmileMe Mirror enables the dentist to offer patients a complete Smile Consultation.
Directors
- Last Annual
- March 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- July 31st, 1986
- Public Since
- September 20th, 2001
- No. of Employees
- 16
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 19,995,969
- Address
- Zuiderlaan 1-3, bus 8, GENT, 9000
- Web
- https://www.remedent.com/
- Phone
- +32 92415880
- Auditors
- Vandelanotte Bedrijfsrevisoren
Upcoming Events for REMI
Similar to REMI
Aamaxan Transport
Pink Sheets on Nasdaq
Accelerate Diagnostics
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
FAQ
As of Today at 22:54 UTC, shares in Remedent are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Remedent last closed at $0.01 and the price had moved by -83.33% over the past 365 days. In terms of relative price strength the Remedent share price has underperformed the S&P500 Index by -85.3% over the past year.
There is no consensus recommendation for this security.
Find out moreRemedent does not currently pay a dividend.
Remedent does not currently pay a dividend.
Remedent does not currently pay a dividend.
To buy shares in Remedent you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Remedent had a market capitalisation of $0.20m.
Here are the trading details for Remedent:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: REMI
Based on an overall assessment of its quality, value and momentum Remedent is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Remedent. Over the past six months, its share price has underperformed the S&P500 Index by -83.27%.
As of the last closing price of $0.01, shares in Remedent were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Remedent PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Remedent's management team is headed by:
- Guy De Vreese - CHM
- Philippe Van Acker - CFO
- Fred Kolsteeg - IND